Total Voting Rights

01 August 2017 15:00 BST

Transparency Directive

Voting Rights and Capital

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 July 2017 the issued share capital of AstraZeneca PLC with voting rights is 1,265,794,991 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,265,794,991.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit and follow us on Twitter @AstraZeneca.

Media Relations           
Esra Erkal-Paler  UK/Global  +44 203 749 5638 
Karen Birmingham    UK/Global    +44 203 749 5634   
Rob Skelding   
Matt Kent   
UK/Global   UK/Global  +44 203 749 5821   
+44 203 749 5906 
Jacob Lund    Sweden    +46 8 553 260 20   
Michele Meixell    US    +1 302 885 2677   
Investor Relations
Thomas   Kudsk Larsen   +44 203 749 5712 
Craig   Marks  Finance, Fixed Income, M&A +44 7881 615 764 
Henry   Wheeler  Oncology +44 203 749 5797 
Mitchell   Chan  Oncology +1 240 477 3771 
Lindsey   Trickett  Cardiovascular & Metabolic   Diseases +1 240 543 7970 
Nick   Stone  Respiratory +44 203 749 5716 
Christer   Gruvris Autoimmunity, Neuroscience &   Infection +44 203 749 5711
US toll free +1 866 381 7277

Adrian Kemp

Company Secretary, AstraZeneca PLC

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:


Documents & Links